http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-101344303-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K51-04 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-55 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0033 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K41-0071 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-409 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-409 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-4985 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K51-04 |
| filingDate | 2011-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2013-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2013-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-101344303-B1 |
| titleOfInvention | Selective Conjugates to Tumors for Targeted Therapy |
| abstract | FIELD OF THE INVENTION The present invention relates to conjugates that are selective for tumors in relation to targeted therapy, and more particularly targeted therapy characterized by combining the properties of light and acoustic hypersensitivity agents, angiogenesis inhibitors and tyrosine kinase inhibitors. It relates to a conjugate that is selective for tumors. The conjugate may be characterized by comprising light and acoustic hypersensitivity agents, angiogenesis inhibitors and tyrosine kinase inhibitors, target ligands and linkers. Tumor-selective conjugates and their application to the target therapies of the present invention are more specifically and pharmacologically related to photodynamic therapeutics and have the properties of angiogenesis and tyrosine kinase inhibitors, cancer and Medicines for the treatment of other diseases can be used in the manufacture. In particular, the present invention relates to the preparation of drugs based on curcuminoids and porphyrin conjugates, and compounds based on curcuminoids and porphyrins conjugates for the treatment of cancer and other disease states. The invention also relates to a therapy based on this composition, which can provide the anticancer, antiangiogenic, inhibitory effect of the proposed drug, and has excellent solubility, bioavailability, stability in aqueous solution, toxicity in the treatment of cancer and other diseases. It has the beneficial effect of lack. Furthermore, the present invention can be used for oral, nasal and rectal administration for the treatment of cancer and other disease states. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190000971-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102248449-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102065711-B1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-20190083478-A |
| priorityDate | 2011-10-07-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 762.